Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Cash & Equivalents (2020 - 2025)

Definitive Healthcare (DH) has disclosed Cash & Equivalents for 6 consecutive years, with $163.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 55.28% year-over-year to $163.6 million, compared with a TTM value of $163.6 million through Dec 2025, up 55.28%, and an annual FY2025 reading of $163.6 million, up 55.28% over the prior year.
  • Cash & Equivalents was $163.6 million for Q4 2025 at Definitive Healthcare, up from $108.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $387.5 million in Q4 2021 and bottomed at $77.5 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $155.9 million, with a median of $131.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 1464.13% in 2021, then tumbled 66.15% in 2023.
  • Year by year, Cash & Equivalents stood at $387.5 million in 2021, then crashed by 62.08% to $146.9 million in 2022, then fell by 10.86% to $131.0 million in 2023, then decreased by 19.54% to $105.4 million in 2024, then surged by 55.28% to $163.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for DH at $163.6 million in Q4 2025, $108.3 million in Q3 2025, and $81.0 million in Q2 2025.